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Aqueous solutions of ceftriaxone in concentrations similar to those achieved in man
and stored at temperatures of 4°C, 22°C and 37°C for up to four weeks were tested
in methylcellulose cultures of normal bone marrow from ten donors.
No significant differences were detected between the colony formation by
neutrophil and macrophage precursors in control cultures and in cultures
containing stored ceftriaxone.
It is concluded that aqueous ceftriaxone solutions stored for up to four weeks at
temperatures up to 37°C are not altered to such an extent that they adversely affect
colony formation by bone marrow progenitor cells from healthy donors.
Introduction
Penicillin and cephalosporin derivatives have been reported to induce neutropenia and
it has been claimed that degradation products of these antibiotics are responsible for
this side effect (Muller et al., 1983).
We therefore studied the influence of stored ceftriaxone, a semi-synthetic
cephalosporin, on colony formation of myeloid precursor cells in vitro, using the
methylcellulose assay.
Materials and methods
Ceftriaxone solutions
A sterile ceftriaxone (Rocephin) solution was prepared at a concentration of
1 mg/ml in redistilled water and stored for up to four weeks at 4°C, at room
temperature (approx. 22°Q and at 37°C. Aliquots of this solution were appropriately
diluted and tested on bone marrow myeloid precursor cells as described below.
Bone marrow cultures
Cryopreserved nucleated bone marrow cells 105/ml, with approximately 90% viability
as determined by trypan-blue exclusion, obtained from ten bone marrow
transplantation donors, were incubated in 5% CO2 at 37°C in a humid atmosphere
in Iscove's modified Dulbecco's medium (Gibco, E 096550). This medium
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Figure 1. Effect of freshly prepared ceftriaxone on colony formation by neutrophil and macrophage
precursors. A , Result of experiment 1 (two bone marrow samples); • , result of experiment 2 (two bone
marrow samples). Stippled — therapeutic plasma ceftriaxone concentration (peak plasma concentration
obtained 30 min after iv infusion of 0-5 and 1 g of ceftriaxone).
contained 0-8% methylcellulose, 16% fetal calf serum (Gibco), 1% de-ionized and de-
lipidated bovine serum albumin, 360mg/l of human transferrin (Otre) and 16% v/v
human PHA-induced leucocyte conditioned medium (CM). After 14 days, colonies
formed by myeloid precursor cells were counted and differentiated with the aid of an
inverted microscope.
Evaluation and statistics
Results are expressed as arithmetical mean and standard error of the mean (S.E.M.).
For statistical evaluation the non-parametric two-way analysis of variance according
to Friedmann (Siegel, 1956) was used.
Results
As shown in Figure 1, freshly prepared ceftriaxone did not inhibit proliferation of
myeloid precursor cells in concentrations up to 200mg/l, while colony growth was
reduced to about 50% by 500 mg/1 and totally abolished by 1000 mg/1 of ceftriaxone.
Furthermore, no colony growth was observed in cultures containing no ceftriaxone
and no CM.
Based on these results, concentrations of 100 mg/1 of ceftriaxone were added to the
cultures in the subsequent storage experiments. Neither storage at room temperature
(22°C), nor at 4°C or at 37°C for up to 96 h revealed any adverse effect on myeloid
colony growth (Table I), even though a slight yellowish colour was observed in
aqueous ceftriaxone solutions kept for 24 h at 37°C. During 24 h, degradation of
ceftriaxone in solution amounted to 1-3% at 22°C and up to 9% at 37°C.
Correspondingly, 11-21% and 4-3%, respectively, of decomposed active substance
was formed at these storage temperatures.
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Table I. Comparison between colony formation by neutrophil and macrophage precursors in
control cultures and in cultures containing aqueous ceftriaxone solutions stored at various
temperatures for up to 96 h
Assay
Number
of
donors
Number of myeloid
colonies (cfu-c)/105
nucleated cells S.E.M.
Computed a
(preassigned
o = 0050)
No ceftnaxone
+ ceftriaxone
+ ceftriaxone
+ ceftriaxone
No ceftriaxone
+ ceftriaxone
+ ceftriaxone
+ ceftriaxone
No ceftriaxone
+ ceftriaxone
+ ceftriaxone
+ ceftriaxone
(0-5
(48
(96
(0-5
(48
(96
(0-5
(48
(96
h/22°Q
h/22°Q
h/22°Q
h/ 4°Q
h/ 4°Q
h / 4°C)
h/37°Q
h /37°Q
h/37°C)
10
10
10
9
10
10
10
9
10
10
10
9
33-2
34-4
341
34-6
35-3
33-7
34-7
34-8
34-3
35-8
33-8
34-8
302
213
212
2-72
2-83
2-42
2-69
2-35
2-56
2-34
2-33
2 21
0-972 = n.s.
0-463 = n.s.
0-339 = n.s.
n.s., No significant differences between colony counts resulting from different storage conditions and those
of the controls.
In order to detect possible effects of prolonged storage, aqueous ceftriaxone
solutions kept for two, three and four weeks at the three temperature levels were
additionally tested on bone marrow cultures from a small number of donors. Again,
myeloid colony growth remained unaffected by the stored ceftriaxone and the results
obtained were in good agreement with those of the control cultures. After aqueous
ceftriaxone solutions had been stored for four weeks and then tested on bone marrow
cultures from two donors, the following numbers of myeloid colonies/105 nucleated
cells were obtained (mean±s.E.M.): controls = 390 ±0, stored ceftriaxone
(22°Q = 38-0 ±2-0; controls = 390 ±60, stored ceftriaxone (4°C) = 38-5 ±4-5;
controls = 40-0 ± 10, stored ceftriaxone (37°Q = 39-5 ±0-5).
Discussion
Neutropenia has occasionally been reported following treatment with high doses of
ceftriaxone, but as yet no proof of a causal relationship between the adverse reaction
and the medication has been produced. The incidence of this side effect during
treatment with ceftriaxone is extremely low and amounts to 0-35-0-54% of the patients
according to literature reviews covering some 1347 publications and presentations and
up to 8565 patients (Havas, Fernex & Kissling, 1983; Fernex, M., Havas, L. &
Kissling, M., unpublished results). Comparative trials with 4100 patients given
ceftriaxone and 4238 patients given standard antibiotic therapy revealed identical
incidences of neutropenia in both groups.
However, in view of the potential therapeutic advantage of parenteral out-patient
therapy in rural areas using pre-prepared ceftriaxone solutions, proof was desired that
stored ceftriaxone solutions do not alter to such an extent that they adversely affect
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colony formation by myeloid bone marrow precursor cells and thus induce
neutropenia.
The use of Iscove's seme-solid culture method was the method of choice as it has
been successfully applied by other authors to investigate similar problems (Negishi &
Young, 1985). Even though our criteria in the study design were very strict, the added
ceftriaxone solutions did not interfere with colony growth by myeloid bone marrow
precursor cells from healthy donors.
This result is comparable to the findings reported by Osterwalder et al. (1986), who
investigated whether or not therapy with cephalosporin alone or combined with other
/Mactam antibiotics (even in doses in excess of 100 g in ten days or more) inhibited
myelopoiesis in vivo in patients with allogeneic bone marrow transplants. These
authors stated that no inhibitory influence of cephalosporin or combinations thereof
with other /J-lactam antibiotics on myelopoiesis was detectable in patients with severe
aplastic anaemia and who had undergone bone marrow transplantation.
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